Full Text Journal Articles by
Author Bernard Zinman

Advertisement

Find full text journal articles






The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis.

Mustafa Tosur, Mario A Cleves, Jay M Sosenko, Ingrid Libman, David A Baidal, Ashok Balasubramanyam, Maria J Redondo, ,

OBJECTIVE:We set forth to compare ethnicities for metabolic and immunological characteristics at the clinical diagnosis of type 1 diabetes (T1D) and assess the effect of ethnicity on beta-cell functional loss within 3 years after clinical diagnosis. RESEARCH METHODS AND DESIGN:We studied participants in TrialNet New Onset Intervention Trials (n = ... Read more >>

J Clin Endocrinol Metab (The Journal of clinical endocrinology and metabolism)
[2020, 105(12):]

Cited: 0 times

View full text PDF listing >>



Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.

João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman, Silvio E Inzucchi,

BACKGROUND:Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect of empagliflozin in patients with MetS enrolled in the EMPA-REG OUTCOME trial. METHODS:A total ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2020, 19(1):200]

Cited: 0 times

View full text PDF listing >>



Advertisement

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



Metabolic Syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A post hoc analyses of the EMPA-REG OUTCOME trial

João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman, Silvio Inzucchi,

Abstract Background : Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect of empagliflozin in patients with MetS enrolled in the EMPA-REG OUTCOME ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.

George Bakris, Megumi Oshima, Kenneth W Mahaffey, Rajiv Agarwal, Christopher P Cannon, George Capuano, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J L Heerspink, Adeera Levin, Bruce Neal, Richard Oh, Carol Pollock, Norman Rosenthal, David C Wheeler, Hong Zhang, Bernard Zinman, Meg J Jardine, Vlado Perkovic,

BACKGROUND AND OBJECTIVES:The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participants with type 2 diabetes mellitus and CKD. Little is known about the use ... Read more >>

Clin J Am Soc Nephrol (Clinical journal of the American Society of Nephrology : CJASN)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial.

Mark A Espeland, Richard E Pratley, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Bernard Zinman, Nikolaus Marx, Darren K McGuire, Knut Robert Andersen, Michaela Mattheus, Annett Keller, Maria Weber, Odd Erik Johansen,

AIMS:Safety is a key consideration for glucose-lowering agents for older people with type 2 diabetes, yet comparative data are limited. We compared the cardiovascular (CV) safety of linagliptin with glimepiride in older and younger participants in the CAROLINA trial in both pre-specified and post-hoc analyses. MATERIALS AND METHODS:People aged 40-85 years ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Bettina J Kraus, Matthew R Weir, George L Bakris, Michaela Mattheus, David Z I Cherney, Naveed Sattar, Hiddo J L Heerspink, Ivana Ritter, Maximilian von Eynatten, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Audrey Koitka-Weber,

Treatment with sodium-glucose co-transporter-2 inhibitors induces an initial 3-5 ml/min/1.73 m2 decline in estimated glomerular filtration rate (eGFR). Although considered to be of hemodynamic origin and largely reversible, this 'eGFR dip' may cause concern in clinical practice, which highlights the need to better understand its incidence and clinical implications. In ... Read more >>

Kidney Int (Kidney international)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.

Ian J Neeland, Bjorn Eliasson, Takatoshi Kasai, Nikolaus Marx, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Isabella Zwiener, Brian S Wojeck, Henry K Yaggi, Odd Erik Johansen, ,

OBJECTIVE:To explore the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its effects on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA in the EMPA-REG OUTCOME trial. RESEARCH DESIGN AND METHODS:Participants with diabetes and CV disease were randomized to empagliflozin (10 and ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(12):3007-3015]

Cited: 0 times

View full text PDF listing >>



Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.

Denice S Feig, Lois E Donovan, Bernard Zinman, J Johanna Sanchez, Elizabeth Asztalos, Edmond A Ryan, I George Fantus, Eileen Hutton, Anthony B Armson, Lorraine L Lipscombe, David Simmons, Jon F R Barrett, Paul J Karanicolas, Siobhan Tobin, H David McIntyre, Simon Yu Tian, George Tomlinson, Kellie E Murphy, ,

BACKGROUND:Although metformin is increasingly being used in women with type 2 diabetes during pregnancy, little data exist on the benefits and harms of metformin use on pregnancy outcomes in these women. We aimed to investigate the effects of the addition of metformin to a standard regimen of insulin on neonatal ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(10):834-844]

Cited: 0 times

View full text PDF listing >>



Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME.

Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann, JoAnn Lindenfeld,

AIMS:The EMPA-REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate the early benefit-risk profile of empagliflozin in patients ... Read more >>

ESC Heart Fail (ESC heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.

Simke W Waijer, Di Xie, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A Inker, Christoph Wanner, Hiddo J L Heerspink,

Background Early reduction in albuminuria with an SGLT2 (sodium-glucose cotransporter 2) inhibitor may be a positive indicator of long-term cardiovascular and renal benefits. We assessed changes in albuminuria during the first 12 weeks of treatment and subsequent long-term cardiovascular and renal risks associated with the SGLT2 inhibitor, empagliflozin, in the EMPA-REG ... Read more >>

J Am Heart Assoc (Journal of the American Heart Association)
[2020, 9(18):e016976]

Cited: 0 times

View full text PDF listing >>



Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.

Michael Böhm, David Fitchett, Anne Pernille Ofstad, Martina Brueckmann, Stefan Kaspers, Jyothis T George, Isabella Zwiener, Bernard Zinman, Christoph Wanner, Nikolaus Marx, Giuseppe Mancia, Stefan D Anker, Felix Mahfoud,

BACKGROUND:The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reduced cardiovascular death or heart failure hospitalizations in type 2 diabetes (T2D) in addition to a reduction of SBP. As heart failure patients often present with low SBP, which can challenge treatment initiation, we explored if empagliflozin's effect on SBP was independent of ... Read more >>

J Hypertens (Journal of hypertension)
[2020, 38(9):1829-1840]

Cited: 0 times

View full text PDF listing >>



Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Silvio E Inzucchi, Kamlesh Khunti, David H Fitchett, Christoph Wanner, Michaela Mattheus, Jyothis T George, Anne Pernille Ofstad, Bernard Zinman,

CONTEXT:Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. OBJECTIVE:To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects the CV benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor. DESIGN:Post hoc analysis. SETTING:Randomized CV outcome trial (EMPA-REG ... Read more >>

J Clin Endocrinol Metab (The Journal of clinical endocrinology and metabolism)
[2020, 105(9):]

Cited: 0 times

View full text PDF listing >>



Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.

Christoph Wanner, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T George, Maximilian von Eynatten, Sibylle J Hauske, ,

AIM:To explore the cardiovascular (CV) and kidney effects of empagliflozin in patients with different clinical phenotypes of diabetic kidney disease (DKD) (i.e. with the presence or absence of overt albuminuria) participating in the EMPA-REG OUTCOME trial. MATERIALS AND METHODS:EMPA-REG OUTCOME randomized participants (1:1:1) to empagliflozin 10 mg, 25 mg or placebo, ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

Subodh Verma, Darren K McGuire, Stephen C Bain, Deepak L Bhatt, Lawrence A Leiter, C David Mazer, Tea Monk Fries, Richard E Pratley, Søren Rasmussen, Hrvoje Vrazic, Bernard Zinman, John B Buse,

Associations between body mass index (BMI) and the cardiovascular (CV) and kidney efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) are uncertain; therefore, data analysed separately from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and the ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Examining the relationship between maternal body size, gestational glucose tolerance status, mode of delivery and ethnicity on human milk microbiota at three months post-partum.

Lauren LeMay-Nedjelski, James Butcher, Sylvia H Ley, Michelle R Asbury, Anthony J Hanley, Alex Kiss, Sharon Unger, Julia K Copeland, Pauline W Wang, Bernard Zinman, Alain Stintzi, Deborah L O'Connor,

BACKGROUND:Few studies have examined how maternal body mass index (BMI), mode of delivery and ethnicity affect the microbial composition of human milk and none have examined associations with maternal metabolic status. Given the high prevalence of maternal adiposity and impaired glucose metabolism, we systematically investigated the associations between these maternal ... Read more >>

BMC Microbiol (BMC microbiology)
[2020, 20(1):219]

Cited: 0 times

View full text PDF listing >>



Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.

Subodh Verma, Stephen C Bain, Julie Broe Honoré, Johannes F E Mann, Michael A Nauck, Richard E Pratley, Søren Rasmussen, Maria Sejersten Ripa, Bernard Zinman, John B Buse,

The randomized, double-blind, cardiovascular outcomes trials LEADER (NCT01179048) and SUSTAIN 6 (NCT01720446) showed cardiovascular risk reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, respectively, compared with placebo. This post hoc analysis examined the impact of microvascular disease at baseline on cardiovascular outcomes in these trials, and ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis.

Vinay Garg, Subodh Verma, Kim A Connelly, Andrew T Yan, Aditya Sikand, Ankit Garg, Paul Dorian, Fei Zuo, Lawrence A Leiter, Bernard Zinman, Peter Jüni, Atul Verma, Hwee Teoh, Adrian Quan, C David Mazer, Andrew C T Ha,

Context:We examined if empagliflozin was associated with modulation of cardiac autonomic tone among subjects with type 2 diabetes and stable coronary artery disease (CAD) relative to placebo. Methods:Using ambulatory 24-h Holter electrocardiographic data prospectively collected from a randomized trial, we compared changes in heart rate variability (HRV) parameters between empagliflozin- ... Read more >>

Metabol Open (Metabolism open)
[2020, 7:100039]

Cited: 0 times

View full text PDF listing >>



Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291-299.

John M Lachin, David M Nathan, Bernard Zinman, Ionut Bebu,

Diabetes (Diabetes)
[2020, 69(7):e7-e8]

Cited: 0 times

View full text PDF listing >>



Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T George, Odd Erik Johansen, Christoph Wanner, ,

OBJECTIVE:Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories (≥60, 45 to <60, 30 to <45, and <30 mL/min/1.73 ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(8):1803-1812]

Cited: 0 times

View full text PDF listing >>



Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, Megumi Oshima, Rajiv Agarwal, George Bakris, Harpreet S Bajaj, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw, Gian Luca Di Tanna, Tom Greene, Hiddo J L Heerspink, Adeera Levin, Bruce Neal, Carol Pollock, Rose Qiu, Tao Sun, David C Wheeler, Hong Zhang, Bernard Zinman, Norman Rosenthal, Vlado Perkovic, ,

BACKGROUND:Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR). METHODS:CREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m2 and substantial albuminuria to ... Read more >>

J Am Soc Nephrol (Journal of the American Society of Nephrology : JASN)
[2020, 31(5):1128-1139]

Cited: 4 times

View full text PDF listing >>



Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.

John B Buse, Stephen C Bain, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Richard E Pratley, Martin Linder, Tea Monk Fries, David D Ørsted, Bernard Zinman, ,

OBJECTIVE:The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist liraglutide versus placebo. The mechanisms behind this CV benefit remain ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(7):1546-1552]

Cited: 0 times

View full text PDF listing >>



Empagliflozin for Patients with Presumed Resistant Hypertension: a Post Hoc Analysis of the EMPA-REG OUTCOME Trial.

João Pedro Ferreira, David Fitchett, Anne Pernille Ofstad, Bettina Johanna Kraus, Christoph Wanner, Isabella Zwiener, Bernard Zinman, Sabine Lauer, Jyothis T George, Patrick Rossignol, Faiez Zannad,

BACKGROUND:Type 2 diabetes (T2D) and resistant hypertension (rHT) often coexist, greatly increasing risk of target-organ damage and death. We explored the effects of empagliflozin in patients with and without presumed resistant hypertension (prHT) in a post hoc analysis of EMPA-REG OUTCOME (NCT01131676). METHODS:Overall, 7020 patients received empagliflozin 10mg, 25mg, or ... Read more >>

Am J Hypertens (American journal of hypertension)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis.

Kristin K Clemens, Mark Woodward, Bruce Neal, Bernard Zinman,

BACKGROUND:Sex differences have been described in diabetes cardiovascular outcome trials (CVOTs). PURPOSE:We systematically reviewed for baseline sex differences in cardiovascular (CV) risk factors and CV protection therapy in diabetes CVOTs. DATA SOURCES:Randomized placebo-controlled trials examining the effect of diabetes medications on major adverse cardiovascular events in people ≥18 years of ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(5):1157-1163]

Cited: 0 times

View full text PDF listing >>



The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.

Erika Opingari, Subodh Verma, Kim A Connelly, Cyril David Mazer, Hwee Teoh, Adrian Quan, Fei Zuo, Yi Pan, Deepak L Bhatt, Bernard Zinman, Lawrence A Leiter, Andrew T Yan, David Z I Cherney, Richard E Gilbert,

Nephrol Dial Transplant (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association)
[2020, 35(5):895-897]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2733 s